Lori J. Pierce, MD, FASTRO, FASCO

Despite the lack of long-term follow-up, abstract discussant Lori J. Pierce, MD, FASTRO, FASCO, Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs, University of Michigan, Ann Arbor, underscored the remarkable potential of short-course radiation to transform the treatment of breast cancer, the most prevalent cancer among women in the United States.

“This study is a game-changer, even for patients who have mastectomy and implant-based reconstruction,” said Dr. Pierce. “It will potentially impact thousands of women.”

As Dr. Pierce reported, hypofractionation in the FABREC study demonstrated equal rates of tumor control, survival, and toxicity, as compared with conventional fractionated radiation. “This is a significant finding, as approximately 40% of patients with breast cancer undergo mastectomy, with two-thirds deciding on implant-based reconstruction,” she said.

Dr. Pierce also emphasized the potential for hypofractionation to minimize treatment breaks and make the treatment procedure more manageable for patients. “Patients have a life, and we want to be able to offer them therapies that work well in their lifestyles,” she noted.

Despite the absence of long-term follow-up results, Dr. Pierce acknowledged the preliminary success of hypofractionation and conveyed optimism based on consistent short-term results. “In every study I am aware of with hypofractionation, there have been no surprises,” she said.

Ultimately, Dr. Pierce commented, these findings could represent a vital shift in managing breast cancer, with hypofractionation being a potentially significant advance for patients. “Without a doubt, these results should be discussed with all patients who have had mastectomy and implant-based reconstruction,” she concluded. “Tell patients what we know and what we still don’t know—but hypofractionation is here to stay and is truly a benefit for our patients.” 

DISCLOSURE: Dr. Pierce reported no conflicts of interest.